AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21712242
Drug: Rifabutin 150
RxNorm normalized name: rifabutin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifabutin 150 mg once daily
Trial: 21712242
Drug: Rifabutin 150
RxNorm normalized name: rifabutin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifabutin 150 mg with atazanavir 300 mg/ritonavir 100 mg once daily
Trial: 21712242
Drug: Rifabutin 150
RxNorm normalized name: rifabutin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifabutin 150 mg three times weekly with atazanavir/ritonavir
Trial: 19584189
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg estradiol combined with 2.5 mg medroxyprogesterone
Trial: 19584189
Drug: 5 mg/d
RxNorm normalized name: Arixtra 5 mg/dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/d oral risedronate (Actonel)
Trial: 7967425
Drug: Immunosuppressive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunosuppressive therapy (IST) using anti-lymphocyte globulin (ALG), cyclosporin A (CSA), and G-CSF
Trial: 7967425
Drug: Standardisation and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardisation and improvement of supportive therapy
Trial: 2890791
Drug: Betaxolol 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betaxolol 0.5% ophthalmic solution
Trial: 28395753
Drug: Selamectin/sarolaner spot-on
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selamectin/sarolaner spot-on formulation (6.0 mg selamectin and 1.0 mg sarolaner per kg bodyweight)
Trial: 28395753
Drug: Selamectin/sarolaner spot-on
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selamectin/sarolaner spot-on formulation
Trial: 25792808
Drug: BP-C1 treatment
RxNorm normalized name: C1-INH
DrugBank: Human C1-esterase inhibitor (DB06404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BP-C1 treatment (daily intramuscular injections for 32 days)
Trial: 25792808
Drug: BP-C1 treatment
RxNorm normalized name: C1-INH
DrugBank: Human C1-esterase inhibitor (DB06404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BP-C1 treatment
Trial: 23327861
Drug: Olopatadine 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olopatadine 5 mg orally twice a day for 14 days
Trial: 23327861
Drug: Cetirizine 10
RxNorm normalized name: cetirizine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine 10 mg orally once a day for 14 days
Trial: 21335259
Drug: Demographic and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Demographic and contextual variables (e.g., ethnicity, gender, marital status, education, smoking in the workplace, number of smokers in the social network, number of supportive others)
Trial: 11723153
Drug: Intramuscular injections
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injections of hydroxycobalamin for 5 months
Trial: 9741608
Drug: Pre‐ and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre‐ and postexercise rectal temperature
Trial: 3132853
Drug: Standard 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard 5% dextrose and electrolyte solutions
Trial: 21679528
Drug: Chinese herbal
RxNorm normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese herbal medicine (Tsang‐Erh‐San extract granules and Houttuynia extract powder) for 8 weeks
Trial: 21679528
Drug: Amoxicillin for
RxNorm normalized name: Amoxicillin for Oral Suspension
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin for 4 weeks
Trial: 20175801
Drug: Fluconazole 50
RxNorm normalized name: fluconazole 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole 50 mg co-administered with halofantrine 500 mg
Trial: 20175801
Drug: Halofantrine 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Halofantrine 500 mg alone
Trial: 11194517
Drug: Infusion warmer
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infusion warmer and standard O.R. draping with two layers of cotton drapes (Group 1)
Trial: 11194517
Drug: Infusion warmer
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infusion warmer and reflecting disposable insulation (Thermadrape) (Group 2)
Trial: 11194517
Drug: Infusion warmer
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infusion warmer and convective air warming with upper body blanket (Group 3)
Trial: 11194517
Drug: Infusion warmer,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion warmer, convective air warming and reflecting disposable insulation (Group 4)
Trial: 28846877
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion (CII) of enoxaparin 40mg over 24h for three consecutive days
Trial: 28846877
Drug: Subcutaneous bolus
RxNorm normalized name: subcutaneous bolus insulin patch pump, 200 unit, disposable 2 unit MISCELL EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous bolus (SCB) administration of enoxaparin 40mg once daily
Trial: 27308826
Drug: Tyloxapol 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tyloxapol 1% (5 ml inhaled three times daily for 3 weeks)
Trial: 27308826
Drug: Saline 0.9%
RxNorm normalized name: CVS Saline 0.9% Nasal Mist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline 0.9% (5 ml inhaled three times daily for 3 weeks)
Trial: 19349629
Drug: Pharmacotherapy supplemented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy supplemented with up to 6 counseling calls (high‐intensity disease management)
Trial: 19349629
Drug: Pharmacotherapy supplemented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy supplemented with up to 2 counseling calls (moderate‐intensity disease management)
Trial: 11386927
Drug: ramipril, 2.5
RxNorm normalized name: Ramipril, 2.5 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ramipril, 2.5 to 10 mg/d
Trial: 11386927
Drug: amlodipine, 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amlodipine, 5 to 10 mg/d
Trial: 9731994
Drug: RBC 400
RxNorm normalized name: Ultratag RBC KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBC 400 mg BID for 4 weeks plus CLR 500 mg TID for the first 2 weeks
Trial: 9731994
Drug: RBC 400
RxNorm normalized name: Ultratag RBC KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBC 400 mg BID for 4 weeks
Trial: 9731994
Drug: CLR 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CLR 500 mg TID for the first 2 weeks
Trial: 7837160
Drug: Comparison group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison group (no etidronate treatment)
Trial: 3422694
Drug: Slow intravenous
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow intravenous infusion of epirubicin
Trial: 3422694
Drug: Bolus injection
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus injection of epirubicin
Trial: 29281033
Drug: Topiramate 200
RxNorm normalized name: topiramate 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate 200 mg/day and Aripiprazole 15 mg/day (combined)
Trial: 25352640
Drug: Acipimox 250
RxNorm normalized name: acipimox 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acipimox 250 mg three times daily for 2 weeks
Trial: 25010608
Drug: Triple-dose albendazole
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triple-dose albendazole
Trial: 19876587
Drug: Camostat mesilate
RxNorm normalized name: Camostat mesilate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camostat mesilate 200 mg three times daily for 2 weeks
Trial: 18373286
Drug: C5: 2
RxNorm normalized name: Cefuroxime
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: C5: 2 x 5-g doses of creatine
Trial: 18373286
Drug: C10: 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C10: 1 x 10-g dose of creatine
Trial: 9847435
Drug: Levalbuterol 0.63
RxNorm normalized name: levalbuterol 0.63 mg/3 mL inhalation solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levalbuterol 0.63 mg
Trial: 9847435
Drug: Racemic albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Racemic albuterol 2.5 mg
Trial: 11011341
Drug: Intracoronary (IC)
RxNorm normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary (IC) adenosine boluses at a dose of 15 to 20 microgram in the right and 18 to 24 microgram in the left coronary artery.
Trial: 11011341
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) adenosine administered as a continuous infusion at a rate of 140 microgram/kg per minute until steady state hyperemia was achieved.
Trial: 8222668
Drug: 5 day
RxNorm normalized name: Fresh 5 Day Deodorant Pads
DrugBank: Aluminum chlorohydrate (DB11573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 day course of external beam radiation therapy followed by enucleation
Trial: 27247914
Drug: Clonidine 0.2
RxNorm normalized name: CLONIDINE 0.2MG/24HR PATCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine 0.2 mg oral 90 minutes before surgery
Trial: 27247914
Drug: Lidocaine 1.5
RxNorm normalized name: LIDOCAINE 1.5%/EPI 1:200000 INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 1.5 mg/kg intravenous 90 seconds before intubation
Trial: 23715582
Drug: Ridaforolimus 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ridaforolimus 40 mg once per day for 5 days every week
Trial: 20884464
Drug: Three prunes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three prunes (11.43g) soaked in water, consumed daily for 8 weeks
Trial: 20884464
Drug: Six prunes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Six prunes (23g) soaked in water, consumed daily for 8 weeks
Trial: 20884464
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group given a glass of water daily for 8 weeks
Trial: 18447225
Drug: Transcutaneous electrical
RxNorm normalized name: Transcutaneous Electrical Nerve Stimulators (TENS Units) MISCELL EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcutaneous electrical acupoint stimulation combined with target-controlled infusion (TCI)
Trial: 21526662
Drug: Target-controlled infusion
RxNorm normalized name: Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor
DrugBank: Tagraxofusp (DB14731)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Target-controlled infusion (TCI)
Trial: 14661563
Drug: Intravenous flurbiprofen
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous flurbiprofen 50 mg
Trial: 14661563
Drug: Suppository indomethacin
RxNorm normalized name: indomethacin Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suppository indomethacin 50 mg
Trial: 11340886
Drug: 2% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lidocaine with 1:200,000 epinephrine and 1 ml of 7.5% sodium bicarbonate
Trial: 11340886
Drug: 2% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lidocaine with 1:200,000 epinephrine and 450 units of hyaluronidase (15 U/ml)
Trial: 8772331
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg of oral salbutamol
Trial: 1602191
Drug: Vaccine group
RxNorm normalized name: MENINGOCOCCAL OLIGOSACCHARIDE VACCINE GROUP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine group (MDT + 8 intradermal injections of M. w. every 3 months)
Trial: 1602191
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (MDT + starch injections as placebo)
Trial: 30809967
Drug: Chiglitazar (CHI)
RxNorm normalized name: Ma Chi Xian
DrugBank: Chiglitazar (DB19023)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chiglitazar (CHI) 48 mg
Trial: 30809967
Drug: Metformin Hydrochloride
RxNorm normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin Hydrochloride (MET) 1000 mg
Trial: 30809967
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of CHI and MET
Trial: 30303516
Drug: Ziv-aflibercept and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziv-aflibercept and high-dose interleukin 2 (arm A)
Trial: 30303516
Drug: High-dose interleukin
RxNorm normalized name: interleukin-11
DrugBank: Oprelvekin (DB00038)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose interleukin 2 alone (arm B)
Trial: 22705426
Drug: Daily distribution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily distribution of RUF-Nias biscuits
Trial: 22705426
Drug: Weekly distribution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly distribution of RUF-Nias biscuits
Trial: 11954880
Drug: Aspirin (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (up to 3g daily)
Trial: 11954880
Drug: Paracetamol (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol (up to 3g daily)
Trial: 11954880
Drug: Ibuprofen (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (up to 1.2g daily)
Trial: 7751888
Drug: Thoracic XRT
RxNorm normalized name: Thoracol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic XRT with cisplatin 70 mg/m2 every 3 weeks for three cycles
Trial: 7751888
Drug: Thoracic XRT
RxNorm normalized name: Thoracol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic XRT alone, 60 to 65 Gy total tumor dose in daily fractions of 1.80 to 2.00 Gy
Trial: 2113611
Drug: Etidronate (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etidronate (400 mg) daily on days 4 through 17
Trial: 2113611
Drug: Etidronate (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etidronate (400 mg) (groups 3 and 4 combined)
Trial: 2113611
Drug: Etidronate (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etidronate (400 mg) (in subgroup with lowest spinal bone mineral density)
Trial: 2113611
Drug: Phosphate (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphate (1.0 g) twice daily on days 1 through 3
Trial: 31973645
Drug: Palliative care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palliative care services provided by a multiprofessional team in the hospital, villages, and homes; short-acting morphine oral solution as the only available strong opioid.
Trial: 31083190
Drug: Neuroendoscopic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuroendoscopic treatment guided by body surface projection
Trial: 25988553
Drug: Fish oil-enriched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil-enriched dairy drink (400 mL/day)
Trial: 25988553
Drug: Control dairy
RxNorm normalized name: Beano Dairy Defense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control dairy drink (400 mL/day)
Trial: 21700966
Drug: Parenteral nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral nutrition supplemented with ω‐3 and ω‐6 fatty acids (Omegaven, 0.2 g/kg/d; Lipovenoes 10%, 0.6 g/kg/d)
Trial: 21700966
Drug: Parenteral nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral nutrition with ω‐6 fatty acid (Lipovenoes 10%, 0.8 g/kg/d)
Trial: 19371322
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 1500 mg tomopenem
Trial: 16513616
Drug: Single-phase whole-body
RxNorm normalized name: Insects (whole body), mite dermatophagoides farinae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-phase whole-body CT scan (90 mL at 1.8 mL/min; delay, 90 s) during normal expiration (protocol B)
Trial: 16513616
Drug: Single-phase whole-body
RxNorm normalized name: Insects (whole body), mite dermatophagoides farinae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-phase whole-body CT scan (90 mL at 1.8 mL/min; delay, 90 s) during shallow breathing (protocol A)
Trial: 12620440
Drug: Rosiglitazone 4
RxNorm normalized name: rosiglitazone 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone 4 mg b.i.d. with placebo (Group I)
Trial: 12620440
Drug: Rosiglitazone 4
RxNorm normalized name: rosiglitazone 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone 4 mg b.i.d. with clomiphene citrate (Group II)
Trial: 10854639
Drug: Venlafaxine monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine monotherapy (225 mg, once or twice daily for 6 weeks)
Trial: 9093725
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus best supportive care
Trial: 8255126
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium 75 mg
Trial: 30211989
Drug: Test dental
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test dental gel containing 2.6% edathamil
Trial: 15974218
Drug: Control gel
RxNorm normalized name: SALICYLIC ACID 20 mg in 1 mL TOPICAL GEL [Walgreens Acne Control Gel]
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control gel
Trial: 18414647
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg albendazole administered every 6 months for 2 years (5 rounds)
Trial: 18414647
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A administered every 6 months
Trial: 7901585
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no albendazole treatment)
Trial: 11868059
Drug: Niacin 50
RxNorm normalized name: niacin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niacin 50 mg administered by mouth 2 times daily for 3 months
Trial: 9878944
Drug: Tasosartan 50
RxNorm normalized name: tasosartan
DrugBank: Tasosartan (DB01349)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tasosartan 50 mg, increased to 100 mg and then to 200 mg if SiDBP > 90 mm Hg
Trial: 7495780
Drug: Interferon-alfa therapy
RxNorm normalized name: Interferon Alfa-2A
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-alfa therapy (3 MU every day for 3 months)
Trial: 7495780
Drug: Interferon-alfa therapy
RxNorm normalized name: Interferon Alfa-2A
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-alfa therapy (3 MU every other day for 3 months)
Trial: 7495780
Drug: Interferon-alfa therapy
RxNorm normalized name: Interferon Alfa-2A
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-alfa therapy (3 MU every other day for 6 months)
Trial: 7495780
Drug: Interferon-alfa therapy
RxNorm normalized name: Interferon Alfa-2A
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-alfa therapy
Trial: 1902264
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous (IV) fentanyl
Trial: 7325630
Drug: Amoxicillin 250
RxNorm normalized name: amoxicillin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin 250 mg twice daily for 4 weeks
Trial: 7325630
Drug: Ampicillin 250
RxNorm normalized name: ampicillin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin 250 mg twice daily for 4 weeks
Trial: 7325630
Drug: Both Amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Both Amoxicillin and Ampicillin
Trial: 7325630
Drug: Amoxicillin and
RxNorm normalized name: omeprazole, amoxicillin and rifabutin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin and Ampicillin
Trial: 23906374
Drug: Empagliflozin 1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 1, 5, 10, 25, or 50 mg QD
Trial: 23906374
Drug: Empagliflozin 5
RxNorm normalized name: empagliflozin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 5 to 50 mg QD
Trial: 21817188
Drug: Drug conservation
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug conservation (DC; interrupt ART until CD4(+) T-cell count <250)
Trial: 15780528
Drug: Transdermal estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal estrogen replacement therapy (TERT) - 100 microg 17beta‐estradiol (Climara forte TTS) once a week for 3 months
Trial: 11900782
Drug: Alcohol (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (target peak BAC of 0.05 g/dl)
Trial: 10527965
Drug: 150 IU
RxNorm normalized name: Follitropin Beta 150 IU/0.5 ML Injection Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 IU recombinant follicle stimulating hormone (recFSH, Puregon)
Trial: 10527965
Drug: 225 IU
RxNorm normalized name: Ascorbic Acid/Calcium Pantothenate/Cyanocobalamin/Iron/Niacin/Pyridoxine/Riboflavin/Thiamine/Vitamin A/Vitamin D/Vitamin E/Zinc 200 MG-18.4 MG-0.005 MG-12 MG-100 MG-4.1 MG-10 MG-0.3 MG-10000 IU-400 IU-225 IU-1.5 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 225 IU highly purified urinary follicle stimulating hormone (uFSH-HP, Metrodin-HP)